NR0B2 and acute kidney injury: FXR agonist (OCA) treatment suppresses the increases in proinflammatory signaling (TNF-α and IL-1β) and the levels of cell-surface adhesion molecules (MCP-1 and ICAM-1) in the cisplatin-induced AKI mouse model by activating the transcription of a small heterodimer partner (SHP; NR0B2), which is known as an FXR target gene.